|
1
|
Zou Z, Anisowicz A, Hendrix MJ, Thor A,
Neveu M, Sheng S, Rafidi K, Seftor E and Sager R: Maspin, a serpin
with tumor-suppressing activity in human mammary epithelial cells.
Science. 263:526–529. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bailey CM, Khalkhali-Ellis Z, Seftor EA
and Hendrix MJC: Biological functions of maspin. J Cell Physiol.
209:617–624. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sheng S, Carey J, Seftor EA, Dias L,
Hendrix MJ and Sager R: Maspin acts at the cell membrane to inhibit
invasion and motility of mammary and prostatic cancer cells. Proc
Natl Acad Sci USA. 93:11669–11674. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang W and Zhang M: Tissue microarray
analysis of maspin expression and its reverse correlation with
mutant p53 in various tumors. Int J Oncol. 20:1145–1150.
2002.PubMed/NCBI
|
|
5
|
Loo JA, Yan W, Ramachandran P and Wong DT:
Comparative human salivary and plasma proteomes. J Dent Res.
89:1016–1023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sopel M, Surowiak P and Berdowska I:
Nuclear maspin expression as a good prognostic factor in human
epithelial ovarian carcinoma. Folia Morphol (Warsz). 69:204–212.
2010.PubMed/NCBI
|
|
7
|
Yin S, Lockett J, Meng Y, Biliran H Jr,
Blouse GE, Li X, Reddy N, Zhao Z, Lin X, Anagli J, et al: Maspin
retards cell detachment via a novel interaction with the
urokinase-type plasminogen activator/urokinase-type plasminogen
activator receptor system. Cancer Res. 66:4173–4181. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Endsley MP, Hu Y, Deng Y, He X, Warejcka
DJ, Twining SS, Gonias SL and Zhang M: Maspin, the molecular bridge
between the plasminogen activator system and beta1 integrin that
facilitates cell adhesion. J Biol Chem. 286:24599–24607. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Odero-Marah VA, Khalkhali-Ellis Z,
Chunthapong J, Amir S, Seftor RE, Seftor EA and Hendrix MJ: Maspin
regulates different signaling pathways for motility and adhesion in
aggressive breast cancer cells. Cancer Biol Ther. 2:398–403. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Biliran H Jr and Sheng S: Pleiotrophic
inhibition of pericellular urokinase-type plasminogen activator
system by endogenous tumor suppressive maspin. Cancer Res.
61:8676–8682. 2001.PubMed/NCBI
|
|
11
|
Alvarez Secord A, Darcy KM, Hutson A,
Huang Z, Lee PS, Jewell EL, Havrilesky LJ, Markman M, Muggia F and
Murphy SK: The regulation of MASPIN expression in epithelial
ovarian cancer: Association with p53 status, and MASPIN promoter
methylation: A gynecologic oncology group study. Gynecol Oncol.
123:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moher D, Liberati A, Tetzlaff J, Altman
DG, Antes G, Atkins D, Barbour V, Barrowman N, Berlin JA, Clark J,
et al: Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA statement. Rev Esp Nutr Hum Diet.
18:172–181. 2014. View Article : Google Scholar
|
|
13
|
Luchini C, Stubbs B, Solmi M and Veronese
N: Assessing the quality of studies in meta-analyses: Advantages
and limitations of the Newcastle Ottawa Scale. World J Meta Anal.
5:80–84. 2017. View Article : Google Scholar
|
|
14
|
Liu W, Zhang XH, Zhang ZG, Wang XL, et al:
The relationship between the maspin, BCSG1 and c-erbB-2 expression
and the prognosis of breast cancer. Chin J Clin Oncol. 32:431–434.
2005.
|
|
15
|
Liu W, Zhang XH, Zhang ZG, Wang XL, et al:
The significance of expression of maspin in breast cancer and
lesions in the neighborhood of cancer. Chin J Clin Oncol.
31:1272–1276. 2004.
|
|
16
|
Hu W and Xing LQ: Significance of maspin
protein expression in breast cancer. Chin J Misdiagnostics.
6:4526–4528. 2006.
|
|
17
|
Zhang W, Wang RY, Li J and Zhang XY:
Expression and clinical significance of Maspin and MMP-2 in breast
infiltrative ductal carcinoma. Chin J Surg Oncol. 6:225–229.
2014.
|
|
18
|
Liu JC, Jiang ZM, Li Xin and Liu XZ:
Expressions of maspin and p53 in breast cancer and its clinical
signifi cance. Chin J Bases Clin Gen Surg. 20:547–550. 2013.
|
|
19
|
Sun G, Shi CQ, Zhang M and Qi Y:
Expression and clinical significance of maspin and p53 in breast
cancer. J Clin Exp Med. 13:328–330. 2014.
|
|
20
|
Yang WP, Wei CY, Zhou HJ, Ding ZL and Li
H: Expression of maspin in 65 cases with breast cancer and its
significance. J Oncol. 16:163–167. 2010.
|
|
21
|
Ding YF, Feng YZ, Ping JL, Wang XH and Li
F: The clinical significance of maspin expression in breast cancer.
Suzhou Univ J Med Sci. 27:396–398. 2006.
|
|
22
|
Cao GF, Zhang CH and You QH: Different
expressions of maspin in human mammary cancer of different ER
expressions. Med J Commun. 20:23–24. 2006.
|
|
23
|
Zhu XQ and Gong DS: Maspin expression in
breast cancer and its relationship with microvessel density. J Surg
Concepts Pract. 12:353–356. 2007.
|
|
24
|
Chen SP, Che AW, Tan XD, Li JL and Kong
JG: Expression and clinicopathological significance of Maspin and
Bmi-1 in breast cancer. Hebei Med J. 37:2774–2776. 2015.
|
|
25
|
Pei XH, Wang F and Yu Z: Expression and
significance of Maspin and uPA in breast cancer. 51:71–72.
2011.
|
|
26
|
Fang F, Li TC and Wu P: Analysis of maspin
protein expression and maspin gene promoter methylation in breast
cancer tissue. Carcinog Teratog Mutagen. 21:42009.
|
|
27
|
Zhang QY, Chen XD, Li JW, Yu HF, Liang QL,
Huang SC and Zhang Z: Expression of vascular endothelial growth
factor and Maspin in breast carcinoma and its clinical
significance. Prog Mod Biomed. 12:493–496. 2012.
|
|
28
|
Zhang W, Qiao SP, Shang PZ, Liu B, Li W
and Nan RL: Clinicopathologic study on expression sleX and maspin
in invasive ductal carcinoma tissue of breast. J Hebei North Univ.
38:1–8. 2022.
|
|
29
|
Liu XZ, Zhou SF, Cai FL, Wu YY and Jin LF:
Expression and clinical significance of maspin and uPA in breast
cancer. J Mod Oncol. 17:2139–2142. 2009.
|
|
30
|
Wang LX, Zhao PR, Wang B, Fan QX, Wang RL
and Zhang GM: The different expression of maspin in human mammary
cancer of different CerbB-2 expression. J Basic Clin Oncol.
18:85–86. 2005.
|
|
31
|
Wakahara M, Sakabe T, Kubouchi Y, Hosoya
K, Hirooka Y, Yurugi Y, Nosaka K, Shiomi T, Nakamura H and Umekita
Y: Subcellular localization of maspin correlates with histone
deacetylase 1 expression in human breast cancer. Anticancer Res.
37:50712017.PubMed/NCBI
|
|
32
|
Tuncel F, Bozkurt F and Berkesoglu M: The
value of maspin and PD-L1 expression and peritumoral lymphocytic
infiltration in breast tumors. Bratisl Lek Listy. 121:894–900.
2020.PubMed/NCBI
|
|
33
|
Feng Y, Zhu J, Shi JP, Wang HL and Zhang
Y: Expression and significances of inhibitors of DNA binding-1,
maspin in invasive ductal cancer with breast infiltrations. J
Lanzhou Univ. 34:42008.
|
|
34
|
Helal DS and El-Guindy DM: Maspin
expression and subcellular localization in invasive ductal
carcinoma of the breast: Prognostic significance and relation to
microvessel density. J Egypt Natl Canc Inst. 29:177–183. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lee MJ, Suh CH and Li ZH:
Clinicopathological significance of maspin expression in breast
cancer. J Korean Med Sci. 21:309–14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kim DH, Yoon DS, Dooley WC, Nam ES, Ryu
JW, Jung KC, Park HR, Sohn JH, Shin HS and Park YE: Association of
maspin expression with the high histological grade and
lymphocyte-rich stroma in early-stage breast cancer.
Histopathology. 42:37–42. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Umekita Y and Yoshida H: Expression of
maspin is up-regulated during the progression of mammary ductal
carcinoma. Histopathology. 42:541–545. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Joensuu KM, Leidenius M, Andersson LC and
Heikkilä PS: High expression of maspin is associated with early
tumor relapse in breast cancer. Hum Pathol. 40:1143–1151. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Prasad CP, Rath G, Mathur S, Bhatnagar D
and Ralhan R: Expression analysis of maspin in invasive ductal
carcinoma of breast and modulation of its expression by curcumin in
breast cancer cell lines. Chem Biol Interact. 183:455–461. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Oliveira AM, Ross JS and Fletcher JA:
Tumor suppressor genes in breast cancer: The gatekeepers and the
caretakers. Am J Clin Pathol. 124 (Suppl):S16–S28. 2005.PubMed/NCBI
|
|
41
|
Zhang B, Liu K and Chen JY: Combination of
5-Aza-CdR and trichostatin A on cell proliferation and maspin gene
expression in breast cancer cell line MDA-MB-435S. Chin J Cancer
Prev Treat. 15:725–728. 2008.
|
|
42
|
Liu HY, Cheng G and Li ZP: The epigenetics
mechanism of maspin silencing in glioma. Yiayao Qianyan.
27:103–105. 2020.
|
|
43
|
Man XB, Tang L, Qiu XH, Yang LQ, Cao HF,
Wu MC and Wang HY: Expression of cytochrome P4502E1 gene in
hepatocellular carcinoma. World J Gastroenterol. 10:1565–1568.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Khalkhali-Ellis Z, Zhang M and Hendrix
MJC: Maspin and cathepsin d partnership in regulating mammary gland
development and breast cancer. Breast Cancer: Causes. Diagnosis and
Treatment. Romero MR: Nova Science Publishers, Inc.; pp. 161–176.
2011
|
|
45
|
Lim S, Hung AC and Porter AG: Focused PCR
screen reveals p53 dependence of nitric oxide-induced apoptosis and
up-regulation of maspin and plasminogen activator inhibitor-1 in
tumor cells. Mol Cancer Res. 7:55–66. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jiang WG, Hiscox S, Horrobin DF, Bryce RP
and Mansel RE: Gamma linolenic acid regulates expression of maspin
and the motility of cancer cells. Biochem Biophys Res Commun.
237:639–644. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yin S, Li X, Meng Y, Finley RL Jr, Sakr W,
Yang H, Reddy N and Sheng S: Tumor-suppressive maspin regulates
cell response to oxidative stress by direct interaction with
glutathione S-transferase. J Biol Chem. 280:34985–3496. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Shui HH, Luo L, Liang SZ, ZHuang L and Li
W: The expression of Maspin protein in oral squamous cell carcinoma
and its significance. Hua Xi Kou Qiang Yi Xue Za Zhi. 26:604–606.
6102008.(In Chinese). PubMed/NCBI
|
|
49
|
Caro AA and Cederbaum AI: Role of
phospholipase A2 activation and calcium in CYP2E1-dependent
toxicity in HepG2 cells. J Biol Chem. 278:33866–33877. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zheng HC and Gong BC: The roles of maspin
expression in gastric cancer: A meta- and bioinformatics analysis.
Oncotarget. 8:66476–66490. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liang XF, Cui ZY, Peng BY, et al: Maspin
and p73 in endometrial cancer tissue Expression level and its
correlation analysis. World's Latest Med Inf Dig. 21:390–391.
2021.
|
|
52
|
Wang Y, Sheng S, Zhang J, Dzinic S, Li S,
Fang F, Wu N, Zheng Q and Yang Y: Elevated maspin expression is
associated with better overall survival in esophageal squamous cell
carcinoma (ESCC). PLoS One. 8:e635812013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yoshizawa K, Nozaki S, Okamune A, Kitahara
H, Ohara T, Kato K, Kawashiri S and Yamamoto E: Loss of maspin is a
negative prognostic factor for invasion and metastasis in oral
squamous cell carcinoma. J Oral Pathol Med. 38:535–539. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Lu M, Li J, Huang Z, Du Y, Jin S and Wang
J: Aberrant maspin mRNA expression is associated with clinical
outcome in patients with pulmonary adenocarcinoma. Med Sci Monit.
22:134–139. 2016. View Article : Google Scholar : PubMed/NCBI
|
